Partnership secures initial clinical and commercial-scale microbial manufacturing capacity The only tri-specific antiviral protein in development, with potential best-in-class potency Clinical studies planned for Q4 2020 Zurich-Schlieren, Switzerland, July 9, 2020.

Proceeds  from the Offering will help accelerate development of the SARS-CoV-2 antiviral candidate, MP0420, as well as early stage clinical and preclinical pipeline assets Zurich-Schlieren, Switzerland, July 7, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is

Proceeds used to accelerate early stage pipeline, inclusive of MP0310, MP0317 and the SARS-CoV-2 antiviral program MP0420 Zurich-Schlieren, Switzerland, July 6, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein

NORTH CHICAGO, Ill., June 26, 2020   – Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S.

Zurich-Schlieren, Switzerland, May 15, 2020.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced the presentation of preclinical data from three of the company’s

DARPin® antiviral candidates demonstrate low picomolar potency in live virus assay Candidate construction complete; two candidates ready for preclinical development & manufacturing Therapeutic profile of a highly potent antiviral biologic with a long half-life supports both a prophylactic and

Research & Development Highlights: Abicipar in neovascular wet age-related macular degeneration (nAMD): Presentation of MAPLE data at the 2020 Angiogenesis, Exudation, and Degeneration symposium showed lower rates of intra-ocular inflammation than the rate observed in Phase 3 studies, as well as no

Zurich-Schlieren, Switzerland, April 29, 2020. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, the shareholders of the company approved all

First trispecific anti-COVID-19 therapeutic program: targets three parts of the viral “spike” protein with one drug candidate for broad inhibition of infection and mitigation of future drug resistance Initial testing performed in collaboration with the Swiss Federal Office for Civil Protection

Zurich-Schlieren, Switzerland, March 25, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today published the invitation to the Annual General Meeting 2020. The Annual General Meeting will be held on